Symbiont Conversion is a conceptual framework that proposes a fundamentally new way of addressing one of the most pressing challenges in modern medicine: antimicrobial resistance. Instead of attempting to eliminate harmful microorganisms, this approach explores the possibility of transforming them into beneficial partners.
At its core, Symbiont Conversion refers to the transformation of organisms typically regarded as parasites into symbionts - organisms that coexist with a host in a mutually beneficial relationship. While traditional medical strategies rely heavily on antibiotics and other antimicrobial agents to destroy pathogens, this paradigm suggests a different path: reprogramming these organisms so that they contribute positively to the host rather than harming it.
This shift is particularly relevant in the context of rising antibiotic resistance. As bacteria evolve mechanisms to evade destruction, the effectiveness of conventional treatments continues to decline. Symbiont Conversion offers a potential solution by bypassing the evolutionary arms race altogether. Instead of killing bacteria - which inevitably selects for resistant strains - it aims to alter their behavior, reducing or eliminating their pathogenicity while potentially harnessing their biological functions for the host's benefit.
The Symbiont Conversion Theory postulates that parasites can be influenced - genetically, physiologically, or environmentally - in ways that promote the emergence of symbiotic traits. This could involve modifying gene expression, altering metabolic pathways, or creating conditions that favor cooperative over harmful interactions. In this sense, disease is not only a problem of invasion, but also of dysfunctional relationships between organisms.
Although still in an early conceptual stage, Symbiont Conversion directly addresses the limitations of current antimicrobial strategies. By converting harmful bacteria into non-pathogenic or even beneficial forms, it may be possible to treat infections without contributing to resistance development. This approach could redefine infection control by replacing eradication with functional transformation.
Beyond medicine, the concept has potential applications in agriculture and environmental science, where microbial communities play a crucial role. However, its most immediate and impactful implication lies in offering a novel pathway to manage - and potentially overcome - the global crisis of antibiotic resistance.
Current scientific literature suggests two primary strategies for reprogramming bacteria. One approach involves genetic modification, using tools such as bacteriophages or CRISPR/Cas9 to alter bacterial DNA. These methods are typically performed ex vivo. The second approach focuses on metabolic reprogramming, where bacterial behavior is influenced through environmental or chemical factors - potentially even in vivo.
For Symbiont Conversion to become a viable therapeutic strategy, in vivo methods would be particularly valuable, as they would allow direct treatment within the patient. However, hybrid approaches - where bacteria are modified outside the body and then reintroduced - may serve as an important intermediate step.
The term Symbiont Conversion was coined by Claus D. Volko. The idea emerged from his work in the research group of Dr. Uwe Rohr's, who investigated the biological effects of isoflavones. Rohr hypothesized that these compounds could shift physiological processes from harmful to beneficial states - for example, by converting "stress hormones" into "immunity hormones," or even by reverting cancer cells to normal tissue. Building on this conceptual foundation, Volko extended the principle to microorganisms and parasitic cells in general, leading to the development of Symbiont Conversion Theory.
Claus D. Volko, June 30, 2026